Streetbeat News

RDGL

Vivos Inc

https://www.radiogel.com/

CEO

James Katzaroff

Employees

Industry

Surgical and Medical Instrument Manufacturing

Open

0.08

Mkt cap

35M

Volume

1.3M

High

0.08

P/E Ratio

-8.39

52-wk high

0.26

Low

0.08

Div yield

N/A

52-wk low

0.05

Vivos Therapeutics reported a strong Q3 with a 17% increase in revenue and reduced operating expenses, aiming for positive cash flow.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its Q3 2024 financial results on November 14, 2024, after market close. The company specializes in treatments for sleep-related breathing disorders.

Portfolio Pulse from

November 13, 2024 | 10:15 pm

Vivos Inc. has expanded its IsoPet Precision Radionuclide Therapy to include exotic animals. This expansion could potentially increase the company's market reach and revenue streams.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:31 pm

Insiders are buying shares of Pineapple Financial Inc. (NYSE:PAPL) and Vivos Inc. (OTC:RDGL), indicating confidence in these companies despite recent challenges. Pineapple Financial's CSO bought 2,000 shares after a wider-than-expected quarterly loss, while Vivos' CEO acquired 50,000 shares following an FDA application for human clinical trials.

Portfolio Pulse from Avi Kapoor

August 05, 2024 | 1:13 pm

Insiders are buying shares of Vivos Inc. (OTC:RDGL), Alset Inc. (NASDAQ:AEI), and GEE Group Inc. (NYSE:JOB), indicating their confidence in these companies. Vivos' CEO bought 50,000 shares, Alset's CEO acquired 20,312 shares, and GEE Group's Director purchased 300,000 shares.

Portfolio Pulse from Avi Kapoor

June 05, 2024 | 11:16 am

The FDA has granted Breakthrough Device Designation to Vivos Inc.'s RadioGel for treating solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. RadioGel is an injectable brachytherapy device using yttrium-90 for localized radiation treatment. Vivos Inc. plans to expedite its IDE submission for human clinical trials in collaboration with the Mayo Clinic.

Portfolio Pulse from Javier Hasse

December 21, 2023 | 4:58 pm

Insiders at three companies have recently made notable purchases of their own company's stock. Earth Science Tech CEO Giorgio R Saumat bought 102,416 shares at $0.07 each, after the company reported a net profit for its fiscal second quarter. Vivos CEO and President Michael Korenko purchased 100,000 shares at $0.05 each, despite the stock falling 15% over the past six months. Gossamer Bio COO/CFO Bryan Giraudo acquired 200,000 shares at $0.56 each, following a price target increase from $5 to $6 by Wedbush.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 2:31 pm

Insiders at Black Diamond Therapeutics, Bespoke Extracts, and Vivos have recently purchased shares in their respective companies. Black Diamond Therapeutics' 10% owner BB Biotech AG acquired 400,000 shares at an average price of $2.34. Bespoke Extracts' CEO Michael Feinsod bought 3,000 shares at an average price of $0.20. Vivos' CEO and President Micheal Korenko purchased 100,000 shares at an average price of $0.05.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 12:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.